Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
- Resource Type
- Article
- Source
- Hypertension Research; Jan2023, Vol. 46 Issue 1, p108-118, 11p
- Subject
- Language
- ISSN
- 09169636